- Home
- GLUE vs OSBC Comparison
GLUE vs OSBC Comparison
Compare GLUE & OSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | OSBC |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLUE | OSBC |
|---|---|---|
| Price | $18.76 | $20.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $32.00 | $23.50 |
| AVG Volume (30 Days) | ★ 919.5K | 394.5K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.62 |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | $25.20 |
| Revenue Next Year | $2.45 | $3.66 |
| P/E Ratio | $72.42 | ★ $12.89 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $3.76 | $15.28 |
| 52 Week High | $25.77 | $22.43 |
Technical Indicators
Market Signals| Indicator | GLUE | OSBC |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 47.28 |
| Support Level | $17.36 | $19.20 |
| Resistance Level | $20.24 | $21.33 |
| Average True Range (ATR) | 1.05 | 0.54 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 33.02 | 38.68 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.